Description

Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor[1][2].–Applications-Cancer-Kinase/protease-Formula-C22H24ClFN4O3-Citation–References-[1]Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. |[2]Liu X, Li C, et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med. 2022 May 4;28(1):50. |[3]Ware KE, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25;2(3):e39. -CASNumber-184475-35-2-MolecularWeight-446.90-Compound Purity–SMILES-ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Apoptosis;Autophagy;EGFR-Isoform–Pathway-Apoptosis;Autophagy;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK-MCE Product type-GMP Small Molecules